AI-Native Denial Management Is Becoming Healthcare RCM's Premium Exit
Catching a denied claim before it's submitted prices very differently than fighting one after. That gap is why AI-layered revenue-cycle platforms are pulling software multiples while pure services shops stay stuck at staffing-agency prices.
NEW YORK, August 25, 2026. Denial management used to be a back-office cost center, the kind of function nobody at a health system wanted to own. It is becoming the reason one revenue-cycle company sells for a services multiple and another sells for a software multiple.
Between 15 and 25 percent of claims get denied on first submission. Reworking each one costs $25 to $118. Industry estimates put the annual hit to the US health system at roughly $262 billion, and 60 percent of denied claims are never resubmitted at all. The hospital just eats the loss, because chasing a $400 denial isn't worth a biller's afternoon.
The old playbook treated that loss as fixed overhead: human coders working a queue after the fact, filing appeals against claims that already bounced. The AI-native version moves the work earlier. Payer-specific rule engines trained on millions of historical claims flag a claim's denial risk before it goes out the door, verify eligibility and prior authorization in real time, and draft appeal language automatically for whatever still gets kicked back. Catching a denial before submission and fighting one after are not the same business, and they don't price the same either.
That gap shows up directly in exit multiples. A pure RCM services shop, bodies working queues, trades at 8 to 10 times EBITDA, a staffing-agency multiple for what is functionally a staffing business. Wrap the same claims volume in a defensible AI layer with a real ROI story ("we recovered $4 million in denied claims last quarter") and it prices at 15 to 20 times ARR. Buyers aren't paying for headcount anymore. They're paying for a system that's painful to rip out once it's embedded in a hospital's EHR workflow, and embedded systems don't get re-bid every renewal cycle the way a services contract does.
The likely acquirers are the large RCM incumbents: Waystar, Optum, Cotiviti, R1. Each would rather buy the AI layer than build it against a live customer base and risk the migration. Waystar's 2024 IPO was its own signal that public markets will underwrite a software multiple for a company still doing plenty of the same blocking-and-tackling as its services-only competitors, as long as enough of it sits inside a platform.
There's real risk sitting under the premium. Payer rules change constantly, so the models need continuous retraining, not a one-time build. Commoditizing foundation models could compress the AI premium as the underlying capability turns into table stakes. And diligence teams have gotten sharper about telling apart platforms doing genuine machine learning on payer behavior from robotic process automation wearing an AI label. That scrutiny is what keeps the premium tied to actual defensibility instead of a multiple that unwinds the first time a buyer opens the hood.
The bet underneath all of it: own the moment before the denial happens, not the appeals process after. That's the platform. Everything downstream of it is still services.